ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells
, is announcing that the Board of Directors will propose the appointment of Jean-Paul Kress as a Director at the Annual General Meeting on June 21, 2019, with a view to appointing him as Chairman of the Board of Directors. Dr. Kress possesses over 25 years’ experience as a senior executive in international biotech and pharma groups.
“I’m delighted that Jean-Paul Kress has agreed to join us to chair our Board of Directors. With our decision to split the duties of Chairman from those of Chief Executive Officer, we are taking concrete steps to enhance our governance strategy in preparation for the next stages in our Company’s development,” commented Gil Beyen, currently ERYTECH’s Chairman and Chief Executive Officer, who will stay on as Chief Executive Officer and a Director. “This represents a unique opportunity for us since Jean-Paul is well-known in the biopharmaceutical industry for his scientific and operational expertise, and for his international network of contacts, both of which will be highly beneficial for ERYTECH”.
Dr. Kress, M.D., was President and Chief Executive Officer and a member of the Board of Directors of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018 for up to $1.2 billion. Prior to joining Syntimmune, Dr. Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Previously, Dr. Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a leading European vaccine company. Prior to this, Dr. Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe.
He was a member of Sarepta Therapeutics’ Board of Directors from 2015 until 2017.
Jean-Paul Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees from École Normale Supérieure in Paris.
Dr. Kress commented: “I am excited to join ERYTECH at this stage of its development, not far from a expected commercial launch. ERYTECH stands out clearly among biotech companies with its unique high-potential technology, supported by a large volume of promising clinical data. I would like to thank Gil Beyen and ERYTECH’s Board of Directors and look forward to a productive collaboration.”
About ERYTECH: www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.
ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.
ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).
ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently completed construction in Princeton, New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
CFO & COO
Mathilde Bohin / Louis-Victor Delouvrier
|+33 4 78 74 44 38
|+33 1 44 71 94 94
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Hoylu AB: Publicerar årsredovisning för 20192.6.2020 23:30:00 CEST | Pressemelding
Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2019 finns tillgänglig på bolagets hemsida: https://www.hoylu.com/investor-relations/financial-reports/ För ytterligare information, vänligen kontakta: Stein Revelsby, VD på Hoylu + 1 213 440 2499 e-post: email@example.com Karl Wiersholm, CFO på Hoylu + 1 425 829 2316 e-post: firstname.lastname@example.org Om Hoylu Hoylus uppdrag är att göra distansarbete och informationsutbyte enkelt. Genom vår anpassningsbara Connected Workspaces™ levererar vi programvarulösningar till företag, organisationer och individer i praktiskt taget alla branscher som gör det möjligt för alla team, stora som små att arbeta effektivt och säkert i ett intuitivt och enkelt arbetsflöde. För mer information: www.hoylu.com Kortnamn: Hoylu Marknadsplats: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB + 46 (0) 8 50 301 550, email@example.com Publicering Denna information är sådan information som Hoylu AB (publ) är skyldig att offentliggöra enli
Hoylu AB: Publishes its Annual Report for 20192.6.2020 23:30:00 CEST | Press release
Hoylu AB (publ) announced today that the Annual Report for 2019 is available at Hoylu’s web site: https://www.hoylu.com/investor-relations/financial-reports/ For more information, please contact: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: firstname.lastname@example.org Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: email@example.com About Hoylu Hoylu’s mission is to make remote work and information sharing easy. Through our customizable Connected Workspaces™ we deliver software solutions for companies, organizations and individuals across virtually all industries that enable all teams, big and small to work efficiently and securely in an intuitive and easy workflow. For more information: www.hoylu.com. Ticker symbol: Hoylu Marketplace: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, firstname.lastname@example.org Publication This information is information that Hoylu AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was s
Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis2.6.2020 22:05:00 CEST | Press release
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected in September 2020. “Novartis will continue to work with the FDA to complete the review as soon as possible,” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “We are well prepared and ready to launch ofatumumab upon approval. We are committed to the MS community and look forward to bringing this important advancement to patients with MS.” Additional regulatory filings are currently underway and regulatory approval for ofatumumab in Europe is expected by Q2 2021. About ofatumumab Ofatumumab (OMB 157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-adminstered by a o
TIGO is recognized once again as a leading Great Place to Work in Latin America2.6.2020 21:16:48 CEST | Press release
TIGO is recognized once again as a leading Great Place to Work in Latin America Luxembourg, June 2nd, 2020 - Millicom’s TIGO operations were ranked among the Top 25 Best Multinational Workplaces in Latin America, across all industries, obtaining the 13th place in the 2020 Great Place to Work® (GPTW) ranking. With more than 20,000 employees in the region, this marks TIGO’s third year ranking as a Great Place to Work. “In today’s world, where uncertainty reigns, our purpose to build digital highways that connect people, improve lives, and develop communities, has never been more important. Our TIGO people make our critical work possible every day and are a vital part of the communities they serve. Through their passion they very much represent what makes TIGO a special place to work, and this recognition continues to validate the extraordinary work we can do as a team,” said Mauricio Ramos, CEO of Millicom. “I am extremely proud and thankful to everyone in our team who continue to demons
INDKALDELSE til ordinær generalforsamling i FLSmidth & Co. A/S2.6.2020 14:46:17 CEST | pressemeddelelse
Company Announcement No. 10-2020 Bestyrelsen indkalder herved til ordinær generalforsamling fredag den 26. juni 2020 kl. 16.00 på selskabets adresse, Vigerslev Allé 77, 2500 Valby. Af hensyn til alles sikkerhed og for at mindske risikoen for smittespredning af COVID-19 henstiller vi til, at vores aktionærer ikke møder op fysisk på generalforsamlingen, men brevstemmer eller giver fuldmagt og følger generalforsamlingen via livestreaming på hjemmesiden. Ledelsen vil også være meget begrænset repræsenteret for at mindske smitterisikoen. Dagsorden: Bestyrelsens beretning om selskabets virksomhed i 2019Forelæggelse og godkendelse af årsrapport for 2019Godkendelse af honorarer til bestyrelsen: a. Endelig godkendelse af honorarer for 2019 Bestyrelsen foreslår uændret godkendelse af honorarerne for 2019, som blev forhåndsgodkendt af generalforsamlingen i 2019. Honorarerne er baseret på et grundhonorar på DKK 450.000 (”Grundhonoraret”) med dobbelt honorar til næstformanden og tredobbelt honorar
NOTICE TO CONVENE the Annual General Meeting of FLSmidth & Co. A/S2.6.2020 14:46:17 CEST | Press release
Company Announcement No. 10-2020 The Board of Directors hereby convenes the Annual General Meeting to be held on Friday 26 June 2020 at 4 pm (CET) at the offices of the company, Vigerslev Allé 77, DK-2500 Valby. To protect everyone’s safety and reduce the risk of COVID-19 spreading, we recommend that shareholders refrain from attending the general meeting in person and instead cast their votes by postal vote or proxy and attend the live webcast of the general meeting via the web site. The number of representatives from the management will be reduced to reduce the risk of infection. Agenda: The Board of Directors' report on the company’s activities in 2019.Presentation and approval of the 2019 Annual Report.Approval of the Board of Directors’ fees: a. Final approval of fees for 2019. The Board of Directors proposes unchanged approval of the fees for 2019 that were pre-approved by the general meeting in 2019. The fees are based on a base fee of DKK 450,000 (the “Base Fee”) with twice tha